925434-55-5 Usage
General Description
A cell-permeable quinolinecarboxamide compound that is shown to inhibit the mitochondrial SIRT3 in a substrate AceCS2-competitive (Ki = 0.56 μM; Km = 2.44 μM), but NAD+-uncompetitive (Ki = 0.34 μM; Km = 280 μM), manner. Also reported to decrease cellular p53 Lys382 acetylation (Effective conc. = 10 μM in U2OS and MEF cultures) and inhibit p300 HAT activity (IC50 = 9 μM) in vitro, as well as offer therapeutic benefits in several murine and rodent type 2 diabetes models (100 mg/kg/dayl p.o.) in vivo. Whether and how SRT1720 activates SIRT1 activity remains uncertain. Also available as a 25 mM solution in DMSO (Cat. No. 530748).
Check Digit Verification of cas no
The CAS Registry Mumber 925434-55-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,5,4,3 and 4 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 925434-55:
(8*9)+(7*2)+(6*5)+(5*4)+(4*3)+(3*4)+(2*5)+(1*5)=175
175 % 10 = 5
So 925434-55-5 is a valid CAS Registry Number.
925434-55-5Relevant articles and documents
Discovery of imidazo[1,2-6]thiazole derivatives as novel SIRT1 activators
Vu, Chi B.,Bemis, Jean E.,Disch, Jeremy S.,Ng, Pui Yee,Nunes, Joseph J.,Milne, Jill C.,Carney, David P.,Lynch, Amy V.,Smith, Jesse J.,Lavu, Siva,Lambert, Philip D.,Gagne, David J.,Jirousek, Michael R.,Schenk, Simon,Olefsky, Jerrold M.,Perni, Robert B.
experimental part, p. 1275 - 1283 (2009/12/07)
A series of imidazo[1,2-b]thiazole derivatives is shown to activate the NAD+-dependent deacetylase SIRT1, a potential new therapeutic target to treat various metabolic disorders. This series of compounds was derived from a high throughput scree
